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Neurodegenerative diseases are characterized by the progressive degeneration of
neurons in the central and peripheral nervous system (CNS, PNS), resulting in a
reduced innervation of target structures and a loss of function. A shared characteristic
of many neurodegenerative diseases is the infiltration of microglial cells into affected
brain regions. During early disease stages microglial cells often display a rather
neuroprotective phenotype, but switch to a more pro-inflammatory neurotoxic phenotype
in later stages of the disease, contributing to the neurodegeneration. Activation of
the Rho kinase (ROCK) pathway appears to be instrumental for the modulation of the
microglial phenotype: increased ROCK activity in microglia mediates mechanisms of the
inflammatory response and is associated with improved motility, increased production
of reactive oxygen species (ROS) and release of inflammatory cytokines. Recently,
several studies suggested inhibition of ROCK signaling as a promising treatment option
for neurodegenerative diseases. In this review article, we discuss the contribution
of microglial activity and phenotype switch to the pathophysiology of Parkinson’s
disease (PD) and Amyotrophic lateral sclerosis (ALS), two devastating neurodegenerative
diseases without disease-modifying treatment options. Furthermore, we describe how
ROCK inhibition can influence the microglial phenotype in disease models and explore
ROCK inhibition as a future treatment option for PD and ALS.
Keywords: microglial polarization, Parkinson’s disease, amyotrophic lateral sclerosis, ROCK, ROCK inhibition,
neuroinflammation
INTRODUCTION
The idea that neurodegenerative disorders (NDD) are primarily caused by a particular susceptibility
of neuronal subpopulations to damaging insults is challenged by the observation that a pronounced
infiltration of microglia into affected brain regions is a common hallmark of NDD. The discovery of
a microglial phenotype switch from an immune-suppressive neuroprotective to a pro-inflammatory
neurotoxic phenotype emphasizes the importance of a microglial contribution to the formation
and course of NDD. One major regulator of microglial activity is the Rho-kinase (ROCK) signaling
pathway. ROCK is a serine/threonine kinase that is expressed as two homologs, ROCK1 and
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ROCK2. The two isoforms share similar structure and function,
but show differences in their abundance. ROCK1 is the dominant
form in liver, lung, testes, blood and the immune system, whereas
ROCK2 is dominant in the brain and muscles (Nakagawa et al.,
1996; Hashimoto et al., 1999). ROCK activity is regulated by
its upstream regulators, the Rho-GTPases RhoA and RhoC,
which belong to the Ras-superfamily (Leung et al., 1996;
Hashimoto et al., 1999). Active ROCK phosphorylates numerous
downstream targets which are involved in regulation of cell shape
and motility as well as apoptosis and cell survival. In microglial
cells the ROCK pathway is involved in regulation of migration,
phagocytosis and release of inflammatory cytokines and thus
mediates the microglial phenotype (Yan et al., 2012; Borrajo
et al., 2014a). Additionally, there is accumulating evidence that
ROCK is increased in microglial cells in Parkinson’s disease
(PD) and Amyotrophic lateral sclerosis (ALS; Conti et al.,
2014; Saal et al., 2017). Thus, inhibition of the ROCK pathway
could be a promising treatment option for NDD. In this
review article, we show how ROCK inhibition can influence the
microglial phenotype, discuss the microglial contribution to the
pathophysiology of PD and ALS and explore ROCK inhibition as
a treatment option for PD and ALS.
MICROGLIAL POLARIZATION AND
PHENOTYPES
Microglia are the resident innate immune cells with a
macrophage-like capacity in the otherwise immune-privileged
central nervous system (CNS; Kettenmann et al., 2011).
Microglial cells fulfill a broad variety of functions and can
commit to different reactive phenotypes (Schwartz et al., 2006;
Hanisch and Kettenmann, 2007). In the healthy brain microglia
occur in a so-called ‘‘resting’’ state with a ramified phenotype,
which presents highly motile processes that continuously
scan their environment. The processes can detect even slight
aberrations in neural signal propagation and in occurrence and
quantity of extracellular molecules. Thus, ‘‘resting’’ microglia
serve mainly in the surveillance and maintenance of the CNS
homeostasis (Kettenmann et al., 2011; Wolf et al., 2017). Under
pathological conditions microglia can be ‘‘activated’’, e.g., by
infectious agents, tissue damage or functional modifications
of neighboring neurons. This is accompanied by a drastic
morphological change towards an ameboid phenotype and an
altered expression of surface molecules and releasable factors
(Kettenmann et al., 2011; Hu et al., 2015) that is strongly
dependent on the brain region and the nature of the activating
agent. It was shown that microglia isolated from different
brain regions and the spinal cord differ in the severity of
a pro-inflammatory response (Baskar Jesudasan et al., 2014).
Activated microglia can be classified according to the peripheral
macrophage classification system in ‘‘M1’’ and ‘‘M2’’ microglia,
even though this oversimplified model only represents two
extreme activation states and it has become clear that microglial
activation is a highly dynamic process with more than the two
polarities (Franco and Fernández-Suárez, 2015; Tang and Le,
2016; Wolf et al., 2017). The ‘‘M1’’ phenotype is associated with
the release of proinflammatory cytokines (e.g., TNF-α, IL-1β),
nitric oxide (NO) and reactive oxygen species (ROS) and bears
the risk of harming neuronal cells with prolonged activation
(Hanisch and Kettenmann, 2007; Tang and Le, 2016). The ‘‘M2’’
phenotype provides a rather neuroprotective environment by the
release of anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13)
or growth factors such as TGF-β and promotes tissue repair
and regeneration. A growing body of evidence suggests different
‘‘M2’’ subpopulations with distinct biological functions (Hu et al.,
2015; Tang and Le, 2016).
THE ROLE OF ROCK ACTIVITY FOR THE
INFLAMMATORY RESPONSE OF
MICROGLIA
ROCK activity plays a crucial role in microglial activation. It
has been shown that it is involved in the regulation of key
features of microglial activitiy like migration, phagocytosis and
release of cytokines and chemokines (Barcia et al., 2012; Yan
et al., 2012; Borrajo et al., 2014a). Microglia are migratory cells
that can travel along chemokine gradients towards a site of
infection or injury. Motility is a process that mainly reflects
the dynamic organization of the actin cytoskeleton and that
is critically controlled by the Rho family of small GTPases
(Welch and Mullins, 2002). ROCK maintains stress fibers
and focal adhesions, whereas Rac organizes the formation of
filopodia, both necessary structures for migration (Nobes and
Hall, 1995). For phagocytotic cells like microglia, the remodeling
of the actin cytoskeleton is not only important for migration,
but also enables them to engulf particles and cellular debris.
Even though phagocytosis is initiated by different receptors,
downstream they all lead to activation of Rho GTPases for
remodeling of the actin cytoskeleton (Chimini and Chavrier,
2000). As migration and phagocytosis are strongly dependent
on the actin cytoskeleton the involvement of ROCK activity in
these processes is not surprising. Interestingly, however, ROCK
signaling plays also a role in microglial release of cytokines
and chemokines, a process that is initiated by binding of
ligands to specific surface receptors, e.g., purinergic receptors,
toll-like receptors (TLRs) or angiotensin type receptors (Olson
and Miller, 2004; Inoue, 2006; Rodriguez-Perez et al., 2015).
Activation of purinergic receptors for extracellular nucleotides
leads to microglial motility, chemotaxis and release of cytokines,
NO and superoxides. Downstream of purinergic receptors
different effector molecules are activated, among them JNK
and MAPK signaling pathways and ROCK (Erb et al., 2006;
Färber and Kettenmann, 2006). Another important family of
receptors for the activation of microglia are TLRs. They have
a variety of downstream targets including the RhoA-ROCK
signaling pathway (Oda and Kitano, 2006). Microglial release of
cytokines and chemokines is also mediated by angiotensin type
receptors by activation of the nicotinamide adenine dinucleotide
phosphate (NADPH)-oxidase complex and the ROCK signaling
pathway (Rodriguez-Perez et al., 2015). There are several studies
employing inhibition of ROCK that emphasize the significant
role of this pathway for the microglial activation process. In
a rat model of neuropathic pain, ROCK inhibition prevented
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morphological changes in microglia as well as microglia-
neuron interactions (Tatsumi et al., 2015). In a mouse model
for hypoxia and reoxygenation it was shown that ROCK
inhibition by Fasudil led to a reduced expression of microglial
inducible nitric oxide synthase (iNOS). Furthermore, treatment
with the isoquinoline-type ROCK-inhibitor Fasudil reduced the
microglial release of the pro-inflammatory factors NO, IL-1β,
IL-6 and TNF-α (Ding et al., 2010). Similar findings were made
in the rat retina (Tura et al., 2009). Additionally, there is strong
evidence that the ROCK pathway is involved in modulation of the
microglial phenotype. Even though there are no studies showing
that ROCK activity is increased in a certain microglial phenotype,
there are reports from different models showing that inhibition
of ROCK leads to a phenotypic shift from ‘‘M1’’ towards ‘‘M2’’
microglia, suggesting that ROCK activation is necessary for
maintenance of the pro-inflammatory ‘‘M1’’ phenotype. These
phenotypic shifts were associated with a decrease in the release
of the pro-inflammatory factors NO, IL-1β, IL-6 and TNF-α and
increased the release of the anti-inflammatory factor IL-10 in
cultured microglia (Ding et al., 2010). A similar suppression of
the pro-inflammatory cytokines was observed in a mouse model
after Fasudil-treatment (Tönges et al., 2014). Taken together,
there is robust evidence that ROCK activity plays an important
role in activation of microglia and the determination of its
reactive phenotype.
MICROGLIAL ACTIVITY IN PD
PD is the second most common neurodegenerative disorder
worldwide with a prevalence of about 0.3% in industrialized
countries (Dexter and Jenner, 2013). One of its characteristics
is a progressive degeneration of the dopaminergic nigrostriatal
projections and their cell bodies in the substantia nigra. This
leads to a lack of striatal dopamine and imbalanced basal
ganglia signaling, causing severe motor deficits (Jankovic, 2008).
Approximately 5% of all PD cases are inherited and caused
by mutations in different genes or duplications/triplications
of the α-synuclein locus. However, the majority of the PD
cases occurs sporadically without identifiable cause (Dexter and
Jenner, 2013).
There are numerous in vitro and animal studies suggesting
a link between the loss of dopaminergic neurons and activation
of microglia in the substantia nigra in PD. In animals treated
with the neurotoxins 6-hydroxydopamine (6-OHDA) or
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) an
increased microglial infiltration and activation has been
described (Akiyama and McGeer, 1989; Członkowska et al.,
1996; Cicchetti et al., 2002; Gao et al., 2002; Noelker et al.,
2013). Similar observations could be made in monkeys treated
with MPTP. Here, a prolonged activation of microglia was
observed even 1 year after MPTP treatment (Barcia et al.,
2004). Interestingly, the postmortem tissues of human MPTP
users showed also a prolonged activation of reactive microglia,
even years after the acute intoxication (Langston et al., 1999).
Furthermore, aggregated α-synuclein, one of the main hallmarks
of PD, released from dying neurons leads to a microglial
activation towards the pro-inflammatory ‘‘M1’’ phenotype
(Zhang et al., 2005; Reynolds et al., 2008; Lee et al., 2010). It
is possible to visualize reactive microglia in vivo by positron
emission topography (PET) employing radiotracers that
bind to surface structures of activated microglia, such as the
isoquinoline-derivative and translocator protein (TSPO)-ligand
[11C]-PK11195 (Bartels and Leenders, 2007). Different PET
studies could confirm an increased microglial activation in
the midbrain of PD patients that was correlated to disease
progression (Ouchi et al., 2005; Gerhard et al., 2006; Koshimori
et al., 2015). This goes in line with a study reporting that the
pro-inflammatory cytokines TNFα, IL-6 and IL-1β were elevated
in the cerebrospinal fluid (CSF) of PD patients (Qin et al.,
2016). So far, all evidence on hand points towards an increased
microglial activation with a pro-inflammatory ‘‘M1’’ phenotype
that might contribute to PD progression. Little is known about
the ‘‘M2’’ phenotype in PD.
Abnormal activity of ROCK associated with an increased
inflammatory response was demonstrated in the substantia
nigra of the MPTP mouse model for PD (Villar-Cheda et al.,
2012). Additionally, our group could show that in postmortem
tissue of PD patients compared to age-matched controls ROCK
expression is increased in glial cells (Saal et al., 2017). It has been
shown that, as the two phenotypes can transit into each other,
treatment with a ROCK inhibitor skews ‘‘M1’’ toward ‘‘M2’’
microglia in experimental PD models and thus, is a promising
therapeutic option for the treatment of PD (Zhao et al., 2015; He
et al., 2016; summarized in Figure 1).
MICROGLIAL ACTIVATION IN ALS
ALS is a chronic progressive NDD with a fatal disease course.
Because of the involvement of upper and lower motoneurons
with subsequent impairment of the CNS corticopyramidal tract
and peripheral motor axons patients suffer from progressive
muscle weakness and paralysis, which ultimately leads to death
within 3–5 years. The large majority of ALS is sporadic but
there are also familial cases which have a genetic predisposition
(e.g., mutations in the SOD1 gene or DNA repeat expansions in
C9orf72; Paez-Colasante et al., 2015).
The immune system and neuroinflammation are strongly
implicated in ALS progression and comprise microglial
activation, T-cell-independent macrophage activation, monocyte
recruitment to diseased tissue and dysregulation of immune-
related genes in human ALS patients (Henkel et al., 2013;
Philips and Rothstein, 2014). This neuroinflammatory response
accompanies neuronal cell death with microglial cells being
the first cell type to be activated (Evans et al., 2013). In human
postmortem studies, reactive microglia were detected in regions
which play an important role in motor function (motor cortex,
motor nuclei of the brainstem, corticospinal tract, spinal cord;
Kawamata et al., 1992; Moisse and Strong, 2006). Recently,
microglia were also visualized in ALS patients using integrated
MR/PET and the radioligand [11C]-PBR28 that also binds to
TSPO (Alshikho et al., 2016).
While a functional analysis of microglia in living human
subjects remains difficult, there are various experimental
approaches. In ALS mouse models, microgliosis occurs as well in
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FIGURE 1 | The role of Rho-kinase (ROCK) activity and ROCK inhibition in microglia in Parkinson’s disease (PD) and amyotrophic lateral sclerosis
(ALS). In their physiological “ramified” stage microglia are continuously scanning their environment. For simplification, constitutive ROCK activity is disregarded in this
illustration. Upon binding of pathogen- or danger associated molecular patterns (PAMPs or DAMPs; e.g., α-synuclein) to cell surface receptors microglia are
activated, showing a “M1” phenotype that is associated with increased ROCK activity. This leads to a drastic change in morphology towards an ameboid shape,
release of pro-inflammatory cytokines and chemokines and increased formation of microglia-neuron contacts (“gliapses”). Upon ROCK inhibition by a ROCK inhibitor
the microglial phenotype changes towards a more “M2”-like phenotype, leading to the release of anti-inflammatory cytokines and growth factors and less “gliapse”
formation.
pre-symptomatic as in symptomatic SOD1.G93A mice (Gerber
et al., 2012; Tönges et al., 2014) and in SOD1.G37R mice
(Boillée et al., 2006). Here, in vivo imaging could demonstrate
that microglial cells were highly reactive in pre-symptomatic
stages but lost this ability with disease progression (Dibaj
et al., 2011). Phenotyping of mSOD1.G93A microglia suggests
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a predominant M2-type in early onset SOD1.G93A mice and
a rather classically activated M1-type at end stage (Liao et al.,
2012) indicating that the function of microglia changes during
disease progression and both protective or harmful effects may
be exerted depending on the particular situation (summarized in
Figure 1).
When both, wildtype and mSOD1(G93A) primary microglia
were stimulated with LPS, we observed a strong release of
pro-inflammatory cytokines and chemokines in both microglial
cells types, which was even stronger in the wildtype form
(Tönges et al., 2014). This inflammatory response could
be effectively attenuated when cells were co-treated with
ROCK inhibitor Fasudil. This underlines that ROCK is
considerably involved in the modulation of microglial cell
function. In line with this, SOD1.G93A mice were shown to
exhibit enhanced ROCK activity leading to increased levels
of phosphorylated adducin, elevated PTEN activation and
decreased Akt activity (Takata et al., 2013). In patients with
sporadic ALS, increases of ROCK2 protein have also been shown
and were most prominent in skeletal muscle tissue (Conti et al.,
2014).
ROCK INHIBITION AS A TREATMENT
OPTION FOR PD AND ALS
Therapeutic studies targeting ROCK have been performed in
different models of NDD using different strategies to attenuate
ROCK activity (reviewed in Hensel et al., 2015). Inhibition
of ROCK can be achieved pharmacologically using small
molecules targeting either both ROCK isoforms (e.g., Fasudil
and Y-27632) or specifically ROCK2 (e.g., SR3677 and SLx-2119;
Defert and Boland, 2017). Another approach is the employment
of genetic tools that target ROCK expression (e.g., sh- or
siRNA).
In PD models, several studies using different approaches of
ROCK inhibition have been published (reviewed in Labandeira-
Garcia et al., 2015). In a medium severe subchronic MPTP
mouse model of PD (30 mg/kg body weight for five consecutive
days) oral treatment with Fasudil led to protection of nigral
dopaminergic neurons and preservation of the nigrostriatal
projections, resulting in an improved motor performance
(Tönges et al., 2012). Similar findings were reported in MPTP
treated mice (30 mg/kg body weight for five consecutive
days) that received the ROCK inhibitor Y-27632 (Villar-Cheda
et al., 2012). Interestingly, the effects were attributed both,
to a direct neuroprotective effect, which was also present
in a microglia-free neuronal culture (Tönges et al., 2012),
and to an inhibition of the microglial response (Villar-Cheda
et al., 2012). Another study could show that inhibition of
the microglial response is essential for the neuroprotective
effects of ROCK inhibition in the MPP+-mediated dopaminergic
degeneration (Borrajo et al., 2014b). Additionally, it was shown
that MPTP treatment leads to microglial activation and increased
formation of microglia-neuron contacts, so called ‘‘gliapses’’.
Treatment with Fasudil prevented microglial activation and
led to increased dopaminergic neuron survival (Barcia et al.,
2012).
In another toxin-induced PD model that shows a more
severe lesion, the high dose (4 µg/2 µl) striatal 6-OHDA model,
oral treatment with Fasudil could not reduce dopaminergic
degeneration in mice (Tatenhorst et al., 2014). Using shRNAs
that diminished ROCK2 in nigral neurons in the same model,
we could show decreased dopaminergic cell death in the
substantia nigra. However, striatal fiber density and dopamine
contents were not significantly preserved in these animals (Saal
et al., 2015). So far, there are no descriptions of the effect
of ROCK inhibition on microglial activation in the 6-OHDA
model, even though it is known that microglial activation and
ROS production contribute to 6-OHDA induced dopaminergic
neurodegeneration (Rodriguez-Pallares et al., 2007). The extent
of dopaminergic neuron loss in the two described toxin-induced
PD models is strongly dependent on the dosage and, in the
6-OHDA model, site of administration. The described studies
show that in models with a severe lesion, like the here-described
6-OHDA model, ROCK inhibition alone may not be sufficient to
prevent dopaminergic degeneration.
In a transgenic mouse model expressing human mutated
α-synuclein (aSyn.A53T), oral Fasudil treatment led to decreased
midbrain α-synuclein pathology and improved motor and
cognitive functions (Tatenhorst et al., 2016). Even though the
microglial contribution to the phenotype was not analyzed here,
one could speculate that it plays a role, as aggregated α-synuclein
induces microglial ‘‘M1’’ activity (Reynolds et al., 2008; Lee et al.,
2010).
Taken together, ROCK inhibition leads to protection of
dopaminergic neurons in different models of PD by changing
the microglial activation state and exertion of a direct
neuroprotective effect.
In ALS, animal studies with ROCK inhibitors are limited
to the transgenic SOD1.G93A mouse model. Oral treatment
with Fasudil resulted in a slowed disease progression, increased
survival time and attenuated motor neuron loss (Takata
et al., 2013), which was mediated by decreased PTEN
activation and an increase in PI3K-Akt signaling. Similar
effects were also observed in our own analysis. Additionally,
pre-symptomatically applied Fasudil modified glial responses in
SOD1.G93A mice. While astroglial infiltration in the anterior
horn was decreased, microglia numbers increased with Fasudil
treatment. Furthermore, an in vitro activation analysis of primary
microglia showed that Fasudil changes the release of cytokines
towards an anti-inflammatory profile. Thus, it can be postulated
that Fasudil shifts the microglial phenotype towards ‘‘M2’’ in
SOD1 mice (Tönges et al., 2014). In animals, where the treatment
started with disease onset and thus pathology was already
advanced, survival, basic neurological scoring, motoneuron
pathology and microglial infiltration could not be significantly
improved by Fasudil. However, even in this paradigm the
treated animals showed a better motor performance compared
to non-treated animals (Günther et al., 2017). In another study,
treatment with the 4-aminopyridine ROCK-inhibitor Y-27632
improved motor function in male SOD1.G93A mice (Günther
et al., 2014). Since both Fasudil and Y-27632 are not completely
selective for ROCK, inhibition of other kinases may also
contribute to their effects. Nevertheless, the biological efficacy of
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these two molecules with chemically distinct back bones strongly
argues for ROCK as their main pharmacologically relevant
target.
PHARMACOLOGICAL ROCK INHIBITORS
In recent years a large number of pharmacological ROCK
inhibitors have been developed, most of them belonging either
to the chemical group of isoquinoline derivates (e.g., Fasudil;
Ripasudil) or aminopyridines (e.g., Y-27632; Feng et al., 2016;
Defert and Boland, 2017). The majority of ROCK inhibitors
are Type 1 ATP competitive kinase inhibitors that block the
transfer of the terminal phosphate from ATP to the respective
substrate (Liu and Gray, 2006). In biomedical research Fasudil
and Y-27632 are the most extensively used ROCK inhibitors,
even though they are less selective against different other
kinases and show a limited potency (Feng et al., 2016).
Thus, off-target effects that might have contributed to the
results have to be considered in studies that used these drugs.
Consequently, to date there is only limited data demonstrating
the effect of selective or isoform-selective pharmacological
ROCK inhibition (reviewed in Defert and Boland, 2017).
Development of selective ROCK2 inhibitors would be especially
important for the treatment of NDD as ROCK2 is the dominating
isoform in the CNS. Furthermore, selective ROCK2 inhibition
would minimize the risk of hypotension, a major side effect
of long-term treatment with non-selective ROCK inhibitors.
So far, two ROCK inhibitors have been licensed for clinical
use, both in Japan; Fasudil for the treatment of cerebral
vasospasms (Mueller et al., 2005) and Ripasudil for glaucoma
treatment (Garnock-Jones, 2014). Possible adverse events under
systemic Fasudil treatment are abnormal elevation of liver
enzymes (<2%), renal dysfunction (<2%) and hypotension
(<5%) that occurred in a small number of treated patients,
thus indicating excellent tolerability (Suzuki et al., 2007). In
addition, several new compounds are tested in preclinical and
clinical trials, exploring the potential of pharmacological ROCK
inhibition a promising therapeutic strategy for the treatment of
NDD.
CONCLUDING REMARKS AND
PROSPECTS FOR CLINICAL APPLICATION
Taken together, there is an obvious microglial contribution to the
pathogenesis of PD and ALS and ROCK plays an important role
in mediating the microglial inflammatory response. Different
studies showed that inhibition of ROCK changes the microglial
phenotype from the pro-inflammatory ‘‘M1’’ towards the
beneficial ‘‘M2’’ and that it enhances clinically relevant outcomes
in models of different NDDs making it an auspicious treatment
strategy. Fasudil is already licensed in Japan for the treatment
of vasospasms following subarachnoidal hemorrhage and its
safety for short-term treatment was proven in several preclinical
and clinical trials (Fukumoto et al., 2013; Takata et al., 2013).
As NDDs are chronic diseases, long-term effects of systemic
ROCK inhibition will have to be evaluated, even though first
preclinical long-term studies show excellent tolerability and
safety (Tatenhorst et al., 2016). Translational trials in human
patients are now needed to evaluate the tolerability, safety
and efficacy of ROCK inhibition as a treatment strategy for
NDDs.
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